Article Text

Download PDFPDF

The effects of twice and four times daily zidovudine on p24 antigenaemia in CDC stage II/III patients.
  1. S Gill,
  2. A Tang,
  3. M Cordery,
  4. B Spacey,
  5. G Kelly,
  6. N T Bateman,
  7. D Barlow
  1. Department of GU Medicine, St Thomas' Hospital, London.


    Reduction of HIV p24 antigenaemia by zidovudine was investigated in 34 HIV antibody-positive, asymptomatic patients in a randomised, double-blind, placebo-controlled trial. Zidovudine was shown to lower p24 antigen levels as effectively when administered twice daily as when administered four times daily. Serum levels of p24 antigen varied little over 18 weeks in patients taking placebo.

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.